Skip to main navigation

Topbar Nav

Investor Relations Home
Careers
Connect

Main navigation

Main navigation

News & Events
Stock Information
Corporate Governance
- ESG
- Transparency
Financials & Filings
IR Resources
- Investor FAQs
- Sign-up for Email Alerts

Topbar Nav

Investor Relations Home

Careers

Connect

Event Details

English
German

November 7, 2022: Third Quarter 2022 Earnings

November 7, 2022 at 8:00 AM EST

Add to Outlook

Add to Google Calendar

Before footer menu

Information Request
RSS Feeds

BioNTech SE
An der Goldgrube 12
55131 Mainz
Germany

T: +49 6131 9084-0

For questions on logistics,
handling or other issues:
service@biontech.de

For any other questions, please
use our contact form at
connect.biontech.de

We aspire to utilize the full potential of the immune system to fight cancer and infectious diseases

02. Footer Column2 Links

Connect
Our DNA
How We Translate
Science
For Patients
Investors & Media
Careers

03. Footer Column3 Links

Imprint
Terms Of Use
General Terms and Conditions
General Conditions Of Purchase
Data Privacy Statement
Data Processing Terms Business Partners
Adverse Event Reporting
Cookie Settings

Follow us

© Copyright BioNTech SE . All Rights Reserved.

Our Vision

Our vision: individualize cancer medicine

Leadership

Meet our leadership team

Collaborators

Get to know our partners

Our Locations

Learn about our services

The BioNTech approach

How we approach individualized cancer medicine

mRNA Therapeutics

Why mRNA represents a disruptive new drug class

Antibodies

Beyond mRNA: Expanding therapeutics with our antibody discovery engines

Manufacturing

Manufacturing our own therapeutics

Pipeline

Explore our pipeline

Platforms

Tour our platforms that produce individually-tailored therapeutics

Publications

Browse our research publications

Info & Resources

Our Mission: broaden the therapeutic universe to benefit patients

Clinical trials

Clinical trials currently ongoing